Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ZBIO stock hub

Zenas BioPharma, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ZBIOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ZBIO

In the news

Latest news · ZBIO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-136.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-47.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ZBIO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001953926
Company name	Zenas BioPharma, Inc.
Country	United States
Country code	US
Cusip	98937L105
Employees	167
Employees Change	37%
Employees Change Percent	28.46
Enterprise value	$826.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2024-09-13
Isin	US98937L1052
Last refreshed	2026-05-10
Market cap	$1.2B
Market cap category	Small-Cap
Price	$19.64
Price currency	USD
Rev Per Employee	59,880.24x
Sector	Healthcare
Sic	2834
Symbol	ZBIO
Website	https://zenasbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-32.33%
EV/Sales	82.64x
FCF yield	-14.75%
P/B ratio	4.42x
P/S ratio	116.83x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$10M
Gross Profit Growth	100%
Gross Profit Growth Q	18.28%
Net Income	$-377.7M
Net Income Growth Years	0%
Pretax Margin	-3,778.16%
Profit Per Employee	$-2.3M
ROA	-35.06
ROCE	-65.85
ROE	-136.2
ROIC	-47.44

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	125.35%
EPS Growth Years	2
Revenue Growth	100x
Revenue Growth Years	1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.03
Assets	$383.6M
Cash	$343.2M
Current Assets	$351.2M
Current Liabilities	$62.6M
Debt	$1.3M
Debt Equity	$0.01
Equity	$242.1M
Interest Coverage	-28.85
Liabilities	$141.5M
Long Term Assets	$32.5M
Long Term Liabilities	$78.8M
Net Cash	$341.9M
Net Cash By Market Cap	$29.26
Net Cash Growth	-2.26%
Net Debt Equity	$-1.41
Tangible Book Value	$242.1M
Tangible Book Value Per Share	$4.44

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.61
Net Working Capital	$-53.6M
Quick ratio	5.5
Working Capital	$288.5M
Working Capital Turnover	$0.03

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-238.89%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	125.23%
200-day SMA	24.36
50-day SMA	21.72
50-day SMA vs 200-day SMA	50under200
All Time High	44.6
All Time High Change	-55.96%
All Time High Date	2025-12-24
All Time Low	5.83
All Time Low Change	236.88%
All Time Low Date	2025-01-28
ATR	1.51
Beta1y	0.57
Beta2y	0.57
Ch YTD	-45.91
High	20
High52	44.6
High52 Date	2025-12-24
High52ch	-55.96%
Low	19.01
Low52	8.54
Low52 Date	2025-05-14
Low52ch	130.11%
Ma50ch	-9.57%
Premarket Change Percent	1.92
Premarket Price	$19.64
Premarket Volume	536
Price vs 200-day SMA	-19.39%
RSI	46.44
RSI Monthly	52.65
RSI Weekly	44.76
Sharpe ratio	1.3x
Sortino ratio	1.94
Total Return	-238.89%
Tr YTD	-45.91
Tr1m	-12.63%
Tr1w	1.45%
Tr3m	-9.91%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	4
Analyst Price Target Top	$49.75
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Operating Income	$-211.4M
Operating margin	-2,113.9
Price target	$42.14
Price Target Change	$115
Price Target Change Top	$153

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	36,529,383%
Float Percent	61.41%
Shares Insiders	1.62%
Shares Institutions	60.66%
Shares Out	59,485,518
Shares Qo Q	25.71%
Shares Yo Y	238.89%
Short Float	27.99%
Short Ratio	9.96
Short Shares	17.19

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-198.7M
Average Volume	499,117.95x
Bv Per Share	4.44
CAPEX	$-18,000
Ch1m	-12.63
Ch1w	1.45
Ch1y	125.2
Ch3m	-9.91
Ch6m	-41.57
Change	1.92%
Change From Open	1.92
Close	19.27
Days Gap	0
Depreciation Amortization	56,000
Dollar Volume	5,678,788.2
Earnings Date	2026-03-16
Earnings Time	bmo
EBIT	$-211.4M
EBITDA	$-211.3M
EPS	$-8.44
F Score	2
FCF	$-172.4M
FCF EV Yield	-20.85x
FCF Per Share	$-2.9
Financing CF	215,280,000
Fiscal Year End	December
Founded	2,019
Income Tax	$-79,000
Investing CF	-251,886,000
Ipr	15.53
Iprfo	7.03
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-16
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-16
Ma150	26.53
Ma150ch	-25.98%
Ma20	20
Ma20ch	-1.8%
Net CF	-209,191,000
Next Earnings Date	2027-03-15
Open	19.27
Optionable	Yes
Position In Range	63.64
Post Close	19.64
Postmarket Change Percent	0.36
Postmarket Price	$19.71
Ppne	1,388,000
Pre Close	19.27
Price Date	2026-05-08
Ptbv Ratio	4.82
Relative Volume	0.58x
Revenue	10,000,000x
SBC By Revenue	263.47x
Share Based Comp	26,347,000
Tax By Revenue	-0.79x
Tr6m	-41.57%
Us State	Massachusetts
Volume	289,144
Z Score	-0.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ZBIO pay a dividend?

Capital-return profile for this ticker.

Performance

ZBIO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ZBIO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+60.7%

Float: +61.4% of shares outstanding

Insider ownership

+1.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ZBIO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.4

Neutral momentum band

Price vs 200-day MA

-19.4%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.30

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ZBIO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ZBIO stock rating?

Zenas BioPharma, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ZBIO analysis?

The full report lives at /stocks/ZBIO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ZBIO?

The latest report frames ZBIO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ZBIO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.